Navigation Links
Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates
Date:10/6/2009

WATERTOWN, Mass., Oct. 6 /PRNewswire/ -- Tetraphase Pharmaceuticals Inc. announced today that it has closed the first tranche of its $25 million Series B financing to support the advancement of several novel and potent antibiotic drug candidates. This Series B Financing and first tranche of $10 million was funded by existing investors -- Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090910/NE72856LOGO )

Tetraphase Pharmaceuticals was established in August 2006 to advance and commercialize the ground-breaking synthetic chemistry platform developed by internationally recognized chemist, Dr. Andrew Myers of Harvard University. This proprietary platform overcomes a key barrier to discovering unprecedented classes of antibiotics and other drugs by enabling for the first time their total synthesis from basic building blocks. The initial focus of the company is on the discovery of novel antibiotics to treat drug-resistant infections.

"This is an exciting time for Tetraphase, as we move our lead compound into the clinic and advance our pipeline of novel and potent antibiotic drug candidates," said Guy Macdonald, President and Chief Executive Officer.

About Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals is capitalizing on breakthrough synthetic chemistry technology for drug discovery and development based on a process developed by world leading organic chemist Dr. Andrew Myers of Harvard University. This enabling advance in chemistry provides the company with a broad-range of commercial opportunities across a number of significant disease categories.

SOURCE Tetraphase Pharmaceuticals Inc.


'/>"/>
SOURCE Tetraphase Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Merz Pharmaceuticals Announces Phase III Data for NT 201 in Post-stroke Upper Limb Spasticity
2. Access Pharmaceuticals Signs eMarketing Agreement With iMedicor For MuGard(TM)
3. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
4. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
5. ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results
6. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
7. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Merriman Curhan Ford Acted as Financial Advisor to TorreyPines Therapeutics, Inc. in the Completed Merger With Raptor Pharmaceuticals Corp.
10. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
11. Fovea Pharmaceuticals to be Acquired by sanofi-aventis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2017)... , Sept. 13, 2017   OrthoAtlanta has been ... Atlanta Football Host Committee (AFHC) for the 2018 College Football ... 8, 2018, at Mercedes-Benz Stadium in Atlanta, Georgia ... the AFHC "I,m In" campaign, participating in many activities leading ... ...
(Date:9/12/2017)... LAKES, N.J. , Sept. 12, 2017  Consumer reviews on ... Embrace Hearing as the number one company for hearing aids, ... ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides ...
(Date:9/9/2017)... , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 ... D.C. offering free MRI brain scans to the public.Where:  ... be parked at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... SABRE is raising awareness ... September 11 to the end of November. , The Chicago, Illinois, based self-defense brand ... and teach them about the ease of taking their personal safety into their own ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional Communication:, ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing and ... compliance with FDA rules. , The FDA has issued two draft guidances that ...
(Date:9/21/2017)... ... 2017 , ... Demonstrating a consistent and continued commitment to ... awarded five-year accreditation status through the Public Health Accreditation Board (PHAB). ... a PHAB-accredited health department now extend to more than 203 million people, or ...
(Date:9/21/2017)... ... September 21, 2017 , ... In addition to sticking ... a more holistic approach and use natural alternatives for all house cleaning products, ... certified USDA guaranteeing that, the new line of essential oils, are all 100% ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for Children® (NECC®), a ... of Yie-Hsin Hung to the Board of Directors. , “The New England Center ... Hung is an invaluable addition to our team,” said Vincent Strully, Jr., President and ...
Breaking Medicine News(10 mins):